Dr Reddy’s Laboratories Shares Extend Rise for 6th Day to Hit 52-Week High on High Volumes

DRREDDY Rs 1,376.60 (+1.93%). 52W High Rs 1,414.90 set today intraday. 52W Low Rs 1,148.40. 6th consecutive gain. Nifty Pharma +1.73%. USFDA Form 483 – 7 obs, Bachupally. Vol 4M+.

Dr Reddy’s share price has risen for the sixth consecutive trading session, touching a new 52-week high of Rs 1,414.90 intraday before settling around Rs 1,376.60, still up 1.93% from the previous close of Rs 1,350.50. The six-day winning streak has established a fresh annual high, surpassing the previous 52-week high of Rs 1,375.90 during the day’s session, on trading volumes exceeding 4 million shares. The rally comes even as the USFDA issued a Form 483 with seven observations at Dr Reddy’s biologics manufacturing facility in Bachupally, Hyderabad, following a Pre-License Inspection conducted between June 16 and June 25. Investors are treating the observation report as a standard regulatory interaction rather than a material compliance risk, contributing to the continued strength in the Dr Reddy’s share price.

The Nifty Pharma index is the top performing sector today at +1.73% to 25,402, providing strong sectoral tailwinds to Dr Reddy’s. The Indian Pharmaceutical Market recorded 12.1% year-on-year growth in May 2026, its sixth consecutive month of double-digit domestic IPM expansion, driven simultaneously by volume, pricing and new product introduction. Nomura has a Buy rating on Dr Reddy’s with a target price of Rs 1,740, citing the company’s strategic shift toward branded generics and biosimilar pipeline as re-rating catalysts.

Click Here – Get Free Investment Predictions

Dr Reddy’s Share Price: Live Trading Data

Track Dr Reddy’s Share Price Live on Univest Screener

What Has Driven the 6-Day Dr Reddy’s Share Price Rally?

Three catalysts have converged to power the Dr Reddy’s share price six-day rally. The first is the sustained momentum in the Nifty Pharma index, which has broken above the key 25,000 weekly resistance level on the back of six consecutive months of double-digit Indian Pharmaceutical Market growth. This creates a rising tide effect that lifts all large-cap pharma stocks including Dr Reddy’s. The second catalyst is the company’s near-term product pipeline: Dr Reddy’s received the first-in-Canada approval for generic semaglutide injection, launched the product in India as Obeda on day one, secured USFDA acceptance for review of its abatacept biosimilar IV BLA, and expanded its women’s health portfolio through the acquisition of Progynova and Cyclo-Progynova.

The third catalyst is technical momentum: a breakout above the previous 52-week high of Rs 1,375.90 to touch Rs 1,414.90 today, combined with sustained high volumes, is a classic technical continuation signal. While the stock has pulled back from the intraday high to Rs 1,376.60, the intraday 52-week high breakout itself is a significant positive development for the Dr Reddy’s share price chart structure. Investors are also taking comfort from the fact that the USFDA Form 483 with seven observations at Bachupally is an initial regulatory communication, not a Warning Letter, and the company has a track record of resolving such observations.

Download the Univest iOS App or Univest Android App to access Dr Reddy’s expert research and live price on Univest.

Dr Reddy’s USFDA Form 483: Seven Observations at Bachupally Biologics

The USFDA completed a Pre-License Inspection at Dr Reddy’s biologics manufacturing facility in Bachupally, Hyderabad, between June 16 and June 25, issuing a Form 483 with seven observations. A Form 483 lists conditions that, in the USFDA inspector’s judgment, may constitute deviations from current Good Manufacturing Practices and is an early-stage regulatory communication. It does not represent USFDA’s final determination and is not a Warning Letter, which would be a more serious action. Companies are given 15 business days to submit a corrective action plan. Dr Reddy’s has confirmed it will address all seven observations within the stipulated timeline. A previous Pre-Approval Inspection at the same facility in September 2025 had resulted in five observations, which were resolved satisfactorily.

Conclusion

Dr Reddy’s share price has extended its winning streak to six consecutive sessions, touching a new 52-week high of Rs 1,414.90 intraday before pulling back to Rs 1,376.60. The rally is driven by Nifty Pharma sector strength, a strong pipeline of biosimilar and branded generic products, and high-volume technical confirmation of the breakout above the previous 52-week high. The USFDA Form 483 with seven observations at Bachupally is being treated as a standard regulatory development. Nomura maintains a Buy with target of Rs 1,740. Key monitorables include the corrective action plan for the USFDA observations, abatacept biosimilar BLA review timeline and quarterly results guidance. Always consult a SEBI-registered financial advisor before investing.

Frequently Asked Questions

Why is Dr Reddy’s share price rising for the 6th consecutive day?

Ans. Dr Reddy’s share price has risen for six consecutive sessions on three converging factors: the Nifty Pharma index advancing 1.73% on sustained double-digit IPM growth; a rich near-term product pipeline including first-in-Canada semaglutide approval, Obeda launch in India and abatacept biosimilar BLA under USFDA review; and a technical breakout above the previous 52-week high of Rs 1,375.90 to a new high of Rs 1,414.90.

What was the 52-week high of Dr Reddy’s share price today?

Ans. Dr Reddy’s set a new 52-week high of Rs 1,414.90 in today’s intraday session, surpassing the previous 52-week high of Rs 1,375.90. The current trading price of Rs 1,376.60 reflects a pullback from the intraday peak. The 52-week low is Rs 1,148.40, and the current price represents a 19.9% gain from that low.

What is the USFDA Form 483 with 7 observations for Dr Reddy’s?

Ans. The USFDA completed a Pre-License Inspection at Dr Reddy’s Bachupally biologics facility (June 16-25) and issued Form 483 with seven observations. A Form 483 is an initial regulatory communication that is not a Warning Letter. It lists potential GMP deviations and gives companies time to submit corrective action plans. Dr Reddy’s has committed to address all seven observations within the stipulated timeline.

What is Nomura’s target price for Dr Reddy’s?

Ans. Nomura has a Buy rating on Dr Reddy’s with a target price of Rs 1,740, implying approximately 26.4% upside from the current price of Rs 1,376.60. Nomura cites the company’s strategic shift toward branded generics, women’s health portfolio expansion and biosimilar pipeline as key catalysts for valuation re-rating.

What are the key product launches driving Dr Reddy’s share price?

Ans. Key products supporting the Dr Reddy’s share price include: first-in-Canada approval for generic semaglutide injection and India launch as Obeda; USFDA acceptance for review of abatacept biosimilar IV BLA; Bosutinib 400mg launched in the US under first-to-file exclusivity; and acquisition of Progynova and Cyclo-Progynova to expand the women’s health portfolio.

How much volume is Dr Reddy’s share price trading on today?

Ans. Dr Reddy’s is trading on volumes exceeding 4 million shares in today’s NSE session, well above its average daily trading volume. High volume confirmation of a 52-week high breakout is a technically significant event that analysts often cite as evidence of institutional participation and conviction in the directional move.